BridgeBio’s Achondroplasia Data Portend Competition With BioMarin’s Voxzogo

Already planning to position infigratinib as a safer, more convenient oral therapy for dwarfism compared with the BioMarin injectable, BridgeBio now has Phase II efficacy data showing a higher growth rate.